Biocompatible Delivery System for Metformin: Characterization, Radiolabeling and In Vitro Studies

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61389005%3A_____%2F20%3A00534009" target="_blank" >RIV/61389005:_____/20:00534009 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.2174/1871520620666200423081235" target="_blank" >https://doi.org/10.2174/1871520620666200423081235</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2174/1871520620666200423081235" target="_blank" >10.2174/1871520620666200423081235</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Biocompatible Delivery System for Metformin: Characterization, Radiolabeling and In Vitro Studies

Popis výsledku v původním jazyce

Background: In recent years, the uses of nanotechnology in medicine have an increasing potential as an effective nanocarrier system. These systems are improved with the purpose of maximizing therapeutic activity and minimizing undesirable side-effects. Moreover, radiolabeled nanoparticles can be used as agents for diagnosis and therapeutic purposes in clinical applications. They have three main components: the core, the targeting biomolecule, and the radionuclide.nnObjective: It is aimed to synthesize Metformin (MET) loaded Solid Lipid Nanoparticles (MET-SLN) and radiolabeled with technetium-99m tricarbonyl core.nnMethods: The structure of synthesized nanoparticles was characterized by Fourier Transform Infrared Spectroscopy (FTIR). The particle size and morphology of nanoparticles were examined by Dynamic Light Scattering (DLS), and Scanning Electron Microscope (SEM). Quality control studies of radiolabeled MET-SLN [Tc-99m(CO)(3)-MET-SLN] were performed by High-Performance Liquid Radiochromatography (HPLRC) and Thin Layer Radiochromatography (TLRC).nnResults: The radiolabeling yield of [Tc-99m(CO)(3)-MET-SLN] was found to be 88%. In vitro studies have been performed on cancer lines(MCF7, MDA-MD-231 breast, and HEPG2 liver cancer cells) to determine the biological behavior of Tc-99m(CO)3-MET-SLNs.nnConclusion: The results showed that higher uptake values were observed on estrogen-positive MCF7 breast cancer cell line according to estrogen negative MDA-MB-231 breast cancer and HEPG2 liver cancer cell lines.

Název v anglickém jazyce

Biocompatible Delivery System for Metformin: Characterization, Radiolabeling and In Vitro Studies

Popis výsledku anglicky

Background: In recent years, the uses of nanotechnology in medicine have an increasing potential as an effective nanocarrier system. These systems are improved with the purpose of maximizing therapeutic activity and minimizing undesirable side-effects. Moreover, radiolabeled nanoparticles can be used as agents for diagnosis and therapeutic purposes in clinical applications. They have three main components: the core, the targeting biomolecule, and the radionuclide.nnObjective: It is aimed to synthesize Metformin (MET) loaded Solid Lipid Nanoparticles (MET-SLN) and radiolabeled with technetium-99m tricarbonyl core.nnMethods: The structure of synthesized nanoparticles was characterized by Fourier Transform Infrared Spectroscopy (FTIR). The particle size and morphology of nanoparticles were examined by Dynamic Light Scattering (DLS), and Scanning Electron Microscope (SEM). Quality control studies of radiolabeled MET-SLN [Tc-99m(CO)(3)-MET-SLN] were performed by High-Performance Liquid Radiochromatography (HPLRC) and Thin Layer Radiochromatography (TLRC).nnResults: The radiolabeling yield of [Tc-99m(CO)(3)-MET-SLN] was found to be 88%. In vitro studies have been performed on cancer lines(MCF7, MDA-MD-231 breast, and HEPG2 liver cancer cells) to determine the biological behavior of Tc-99m(CO)3-MET-SLNs.nnConclusion: The results showed that higher uptake values were observed on estrogen-positive MCF7 breast cancer cell line according to estrogen negative MDA-MB-231 breast cancer and HEPG2 liver cancer cell lines.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30224 - Radiology, nuclear medicine and medical imaging

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Anti-Cancer Agents in Medicinal Chemistry

ISSN

1871-5206

e-ISSN

—

Svazek periodika

20

Číslo periodika v rámci svazku

13

Stát vydavatele periodika

AE - Spojené arabské emiráty

Počet stran výsledku

9

Strana od-do

1626-1634

Kód UT WoS článku

000573095600002

EID výsledku v databázi Scopus

2-s2.0-85088953120